WebNov 15, 2024 · C101248, Cerevance’s novel inhibitor, demonstrated a concentration-dependent inhibition of the protein in human and mouse cells expressing THIK-1 with … WebSynopsis Ion channels are important targets for therapeutic intervention due to their extensive roles in human physiology and the pathophysiology of disease. Many successful drugs targeting this gene family have been …
Cerevance Announces Poster Presentation at the BNA …
WebOverall, these data suggest that THIK-1 is a regulator of NLRP3 inflammasome activation in response to ATP and identify THIK-1 as a potential therapeutic target for inflammatory disease. Keywords: NLRP3; THIK-1; inflammasome; inflammation; interleukin-1; potassium channel. © 2024 The Authors. GLIA published by Wiley Periodicals LLC. WebMar 21, 2024 · The discovery of a THIK-1 inhibitor, C101248, and its pharmacological profile, as well as its effect in microglia, is explored. Presenter: Anna Rowland, PhD Session Date and Time: March 27, 2024,... simplot grower solutions sublette ks
Characterisation of C101248: A novel selective THIK-1 channel ... - PubMed
WebNov 15, 2024 · The presentation entitled “ Identification of THIK-1 as a Therapeutic Target For Alzheimer’s Disease: Characterisation of a Selective and Novel Blocker,” demonstrated the power of the proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform in identifying a novel target. Key highlights of the presentation include: Web1 day ago · Title: NETSseq platform identifies KCNK13 (THIK-1) as a target to modulate neuroinflammation in Alzheimer's disease ... Cerevance is a private pharmaceutical company with a focus on CNS disorders ... WebCerevance. 2,081 followers. 1mo. Whether you’re an aspiring CEO or a veteran in the #biotech industry, the latest PM360 Magazine article featuring our CEO, Craig … ray of pat and mike